Physician profile
Joseph E West
NPI 1043375025
$2,599.11
in general payments reported to CMS, 2019-2025
15 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $370 · 2020: $231 · 2021: $344 · 2022: $298 · 2023: $512 · 2024: $460 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,356.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $981.40 | 2019-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $739.32 | 2020-2025 | Nucala |
| Boehringer Ingelheim Pharmaceuticals, INC. | $395.74 | 2019-2023 | Ofev |
| United Therapeutics Corporation | $147.20 | 2021-2024 | Tyvaso |
| Xeris Pharmaceuticals, INC. | $70.53 | 2024-2025 | Gvoke Hypopen |
| Insmed, INC. | $48.67 | 2025 | Arikayce |
| Genentech USA, INC. | $39.95 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $35.77 | 2024 | Dupixent |
| Novo Nordisk INC | $32.62 | 2024-2025 | Rybelsus, Ozempic |
| Actelion Pharmaceuticals US, INC. | $21.90 | 2025 | Opsynvi |
| Merck Sharp & Dohme LLC | $21.42 | 2025 | Winrevair |
| Embecta Corp. | $17.54 | 2024 | |
| Mannkind Corporation | $16.24 | 2025 | |
| Lilly USA, LLC | $15.82 | 2025 | Mounjaro, Zepbound |
| Electromed, INC. | $14.99 | 2025 | Smartvest |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph West listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.